6-K: Transaction Notification
6-K: Gsk's Menveo Meningococcal Vaccine in New Single-Vial, Fully Liquid Presentation Receives Positive European Chmp Opinion
6-K: Zantac (Ranitidine) Litigation - Russell and Hughes Cases
6-K: Blenrep (Belantamab Mafodotin) Combinations in Relapsed/Refractory Multiple Myeloma Accepted for Regulatory Review in Japan
6-K: Blenrep (Belantamab Mafodotin) in Combination Receives Breakthrough Therapy Designation in China for Treatment of Relapsed/Refractory Multiple Myeloma
6-K: Transaction Notification
6-K: Gsk Announces Positive Headline Data from Phase Ii Seasonal Influenza Mrna Vaccine Programme
6-K: Zantac (Ranitidine) Litigation - Dixon Case
6-K: GSK Change of Registered Office Address
6-K: Gsk Provides Update on Phase I/Ii Therapeutic Herpes Simplex Virus (Hsv) Vaccine Trial
6-K: Depemokimab Late-Breaking Data Presented at Ers Show a 54% Reduction in Severe Asthma Exacerbations
6-K: Transaction Notification
6-K: Gsk Announces Positive Results from Phase Iii Trial of Nucala (Mepolizumab) in Copd
6-K: Total Voting Rights and Capital
6-K: European Commission Approves Expanded Age Indication for Gsk's Arexvy, The First Respiratory Syncytial Virus (Rsv) Vaccine for Adults Aged 50-59 at Increased Risk
6-K: Gsk's Nucala (Mepolizumab) Approved in Japan for Treatment of Adults with Chronic Rhinosinusitis with Nasal Polyps
6-K: Bepirovirsen Granted Senku Designation in Japan for Chronic Hepatitis B
6-K: Zantac (Ranitidine) Litigation - Delaware Supreme Court to Review Superior Court's Daubert Decision
6-K: Transaction Notification
6-K: Transaction Notification
No Data
No Data